---
title: "60 Degrees rises as FDA green lights Australian import of anti-malaria drug"
date: "2025-02-12 03:29:44"
summary: "** Specialty pharma firm 60 Degrees Pharmaceuticals' shares rise 5.6% to 63 cents in afternoon trade** Company says the FDA does not object to co's plan to import anti-malaria drug from Australia against any near-term disruption in the U.S.** Arakoda is an antimalarial drug for the prophylaxis of malaria in..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* Specialty pharma firm 60 Degrees Pharmaceuticals' shares rise 5.6% to 63 cents in afternoon trade

\*\* Company says the FDA does not object to co's plan to import anti-malaria drug from Australia against any near-term disruption in the U.S.

\*\* Arakoda is an antimalarial drug for the prophylaxis of malaria in patients aged 18 years and older in the U.S.

\*\* The drug is sold under the brand name Kodatef in Australia

\*\* The drug is not approved for use in the U.S.

\*\* SXTP plans to import a five-month supply of Kodatef while increasing manufacturing of Arakoda over long term

\*\* Co says the two products are identical in their dosing regimens, mechanisms of action, safety and efficacy profiles, and other clinical features

\*\* In the last 12 months, stock has fallen 80.2%

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3P21LO:0-60-degrees-rises-as-fda-green-lights-australian-import-of-anti-malaria-drug/)
